APA (7th ed.) Citation

H, H., MP, D., R, P., RF, H., R, M., N, R., . . . PT, T. (2020). A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC cancer, 20(1), 492. https://doi.org/10.1186/s12885-020-07000-2

Chicago Style (17th ed.) Citation

H, Hasan, et al. "A Phase II Randomized Trial of RAdium-223 Dichloride and SABR Versus SABR for OligomEtastatic Prostate CaNcerS (RAVENS)." BMC Cancer 20, no. 1 (2020): 492. https://doi.org/10.1186/s12885-020-07000-2.

MLA (9th ed.) Citation

H, Hasan, et al. "A Phase II Randomized Trial of RAdium-223 Dichloride and SABR Versus SABR for OligomEtastatic Prostate CaNcerS (RAVENS)." BMC Cancer, vol. 20, no. 1, 2020, p. 492, https://doi.org/10.1186/s12885-020-07000-2.